Sector News

MSD acquires cancer therapeutics developer Modifi Biosciences

October 27, 2024
Life sciences

MSD has acquired US cancer therapeutics developer Modifi Biosciences, a Yale University spinout, enhancing its portfolio with preclinical compounds designed to target DNA repair defects in hard-to-treat cancers.

MSD has acquired all outstanding shares of Modifi Biosciences through a subsidiary for an upfront payment of $30m. The deal also includes potential milestone payments of up to $1.3bn for Modifi’s shareholders.

Modifi Biosciences co-founder Ranjit Bindra stated: “In founding Modifi Biosciences, we sought to radically change the oncology treatment paradigm for cancer patients with glioblastoma and other tumours.

“We are honoured to have Merck recognise the potential of our science, and as an oncology company, they are perfectly positioned to advance our innovations through clinical trials and commercialisation.”

The company’s research, initially published in Science [the peer-reviewed academic journal of the American Association for the Advancement of Science] in 2022, has shown preclinical data across various tumour models, including patient-derived xenograft glioma models.

MSD research laboratories discovery oncology vice-president Dr David Weinstock stated: “DNA repair defects are a frequent hallmark of tumour cells and a major cause of resistance to cancer therapy.

“The talented Modifi Biosciences team has developed an innovative approach that we believe has potential for treating some of the most refractory cancer types”.

Modifi Biosciences co-founder Seth Herzon stated: “We designed our small molecules to have the ability to uniquely overcome clinical resistance mechanisms that have been known for decades but until now have been non-actionable. Additionally, we created the molecules in a manner which allows them to be rapidly progressed from bench to bedside.”

The technology developed by Modifi Biosciences avoids traditional methods that indirectly target proteins in cancer cells. It demonstrated anti-tumour activity in laboratory research, inducing irreparable DNA modifications in cancer cells while sparing healthy tissue.

Source: pharmaceutical-technology.com

comments closed

Related News

November 9, 2024

Biologics CDMO Avid Bioservices to go private with $1.1B sale to Ampersand, GHO Capital

Life sciences

Just days after laying out $90 million to acquire Nektar Therapeutics’ Alabama manufacturing plant, Ampersand Capital Partners is pulling out its life sciences checkbook once again. This week, biologics CDMO Avid Bioservices revealed that it’s agreed to be acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth $1.1 billion.

November 9, 2024

Ardena expands European bioanalytical capabilities

Life sciences

Belgium-headquartered CDMO Ardena announced plans to expand its bioanalytical services in the Netherlands. As part of the investment, the company plans to establish a new bioanalytical laboratory at its Pivot Park facility in Oss, as well as additional capacity and new GLP capabilities at its bioanalytical center of excellence in Assen.

November 9, 2024

Argenx’ Vyvgart launch in CIDP picks up as the company barrels toward 10 indications by 2030

Life sciences

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’s Vyvgart is already making headway in the rare disease space, just one of the long-term growth indications for the versatile medicine.

How can we help you?

We're easy to reach